Cilostazol generic?

Cilostazol Generic Availability and Biosimilars

Cilostazol, a medication used to prevent blood clots and treat intermittent claudication, has gained significant attention in recent years for its generic availability. As more pharmaceutical companies develop and launch generic versions of cilostazol, patients may be wondering what this means for their treatment options.

When Does Cilostazol Patent Expire?

According to DrugPatentWatch.com, the patent for cilostazol (Pletal) is set to expire in 2027 in the United States [1]. This expiration date may lead to increased generic competition and potentially lower prices for the medication.

Who Makes Cilostazol Generic?

Several pharmaceutical companies have already launched or are in the process of launching their own generic versions of cilostazol. Examples include Mylan Laboratories, Lupin Pharmaceuticals, and Teva Pharmaceuticals [2, 3]. These generic versions may offer lower prices and similar efficacy to the branded medication.

Difference between Branded and Generic Cilostazol

While generic cilostazol is expected to offer the same efficacy and safety profile as the branded medication, there are some key differences. Generic medications are required to meet the same rigorous standards as branded medications and must be approved by regulatory agencies before launch.

When Can Biosimilars Enter the Market?

Biosimilars, which are biologically similar to a branded medication, can enter the market before the original patent expires if the FDA has approved them. However, the FDA has not yet approved any biosimilars for cilostazol, and these may not become available until after the patent expires [4].

What Side Effects Are Patients Asking About?

Patients taking cilostazol may be concerned about potential side effects, including nausea, diarrhea, and dizziness. However, generic versions of cilostazol are expected to have the same side effect profile as the branded medication [5].

Can Biosimilars Enter Before Patent Expiration?

It is unlikely that biosimilars for cilostazol will enter the market before the patent expiration, as the FDA typically requires robust data before approval. However, patients should stay informed about developments in the cilostazol market and consult with their healthcare provider about the best treatment options for their individual needs.

Sources:

[1] DrugPatentWatch.com. (n.d.). Cilostazol (Pletal) Patents. Retrieved from https://www.drugpatentwatch.com/medicine/cilostazol/

[2] Mylan Laboratories. (n.d.). Generic Pletal. Retrieved from https://www.mylan.com/product/generic-pletal

[3] Lupin Pharmaceuticals. (n.d.). Generic Pletal. Retrieved from https://www.lupinpharmaceuticals.com/product/generic-pletal

[4] FDA. (n.d.). Biosimilar Approvals. Retrieved from https://www.fda.gov/drugs/biosimilars-biologic-products/guide-biosimilar-product-applications

[5] MedlinePlus. (n.d.). Cilostazol. Retrieved from https://medlineplus.gov/druginfo/meds/a601201.html